7.39
-0.01
(-0.14%)
May 3 - Close
SHA
real-time data -
Disclaimer
Currency in CNY
| Range | - |
| 52 week | 4.71 - 7.52 |
| Open | - |
| Vol. | 0.00 |
| Mkt cap | 2.59B |
| P/E | 55.84 |
| EPS | 0.13 |
| Shares | 350.00M |
Events
May 14, 2013
美罗药业：重大事项延期复牌公告
May 7, 2013
美罗药业：重大事项停牌公告
Apr 27, 2013
美罗药业：2013年第一季度报告
Apr 13, 2013
美罗药业：第五届监事会第三次会议决议公告
Apr 13, 2013
美罗药业：内部控制规范实施工作方案
Apr 13, 2013
美罗药业：控股股东及其他关联方资金占用情况的专项说明
Apr 13, 2013
美罗药业：关于召开2012年度股东大会的通知
Apr 13, 2013
美罗药业：独立董事意见
Apr 13, 2013
美罗药业：独立董事2012年度述职报告
Apr 13, 2013
美罗药业：2012年年度审计报告
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 0.57% | 6.40% |
| Operating margin | -2.46% | 5.36% |
| EBITD margin | - | 7.34% |
| Return on average assets | 0.21% | 3.18% |
| Return on average equity | 0.13% | 5.43% |
| Employees | 789 | - |
| Carbon Disclosure Rating | - | - |
Address
No. 9 Yingsheng Road Yingchengzi Industrial Zone Ganjingzi District
DALIAN, LIA 116036
China
+86-411-84820377 (Phone)
+86-411-84796157 (Fax)
DALIAN, LIA 116036
China
+86-411-84820377 (Phone)
+86-411-84796157 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Merro Pharmaceutical Co., Ltd is principally engaged in the manufacture and distribution of pharmaceuticals. The Company has over 300 products. The Company's western medicines include cardiovascular medicine, digestive medicine, anti-virus medicine, anti-tumor medicine, medicine for diabetes, anti-allergy medicine, among others. The Company has patents of amifostine and leflunomide. The Company also has a range of traditional Chinese medicines, including medicines for bone fractures, heart attacks, gynecological disorders, ichthyosis, stomach, and others.
Officers and directors
| Chenghai Zhang | Chairman of the Board, General Manager | |
| Hao Yu | Chief Financial Officer, Director | |
| Dayong Tang | Chief Operating Officer | |
| Zhiyu Zhu | Chief Administrative Officer | |
| Lihong Zhao | Director of Human Resources | |
| Yongkun Chu | Chief Internal Control Officer, Director | |
| Zhoumin Li | Chief Industrial Officer | |
| Ning Zhang | Secretary of the Board, Director | |
| Tao Mu | Independent Director | |
| Jinxia Wang | Independent Director |